JB/CALL/IDORSIA/10/0.2/20.12.24 | Market Closed - Bid/Ask 11:20:00 2024-06-27 EDT | After market 11:15:00 | |||
| 0.025 CHF | -3.85% |
|
0.023 | -8.00% |
| 1 month | -53.70% | ||
| 3 months | -86.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 0.025 | -3.85% |
| 24-06-25 | 0.026 | -10.34% |
Delayed Quote Swiss Exchange
Last update June 27, 2024 at 11:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | Bank Julius Bär |
| IDINJB | |
| ISIN | CH1259711070 |
| Date issued | 2023-04-13 |
| Strike | 10 CHF |
| Maturity | 2024-12-20 (172 Days) |
| Parity | 5 : 1 |
| Emission price | 0.69 CHF |
| Emission volume | N/A |
| Settlement | both |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.72 CHF |
|---|---|
| Lowest since issue | 0.025 CHF |
| Spread | 0.01 CHF |
| Spread % | 35.71% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.026
CHF
Average target price
1.692
CHF
Spread / Average Target
-16.46%
- Stock Market
- Warrants
- IDINJB Warrant
